<DOC>
	<DOCNO>NCT01274897</DOCNO>
	<brief_summary>This study design evaluate immunogenicity safety quadrivalent vaccine MenACWY-CRM healthy subject 11 55 year age Korea .</brief_summary>
	<brief_title>A Multi-center , Observer-blind , Placebo-controlled , Randomized Study Evaluate Immunogenicity Safety MenACWY Adolescents Adults Korea</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>Individuals eligible enrollment study : 1. 1155 year age inclusive , nature study explain : 1. give write assent and/or parent/legal representative provide write informed consent ( 1119 year age ) . 2. provide write informed consent ( 2055 year age ) . 2. investigator believe parents/legal representative would comply requirement protocol ( e.g. , completion Diary Card , return followup visit ) . 3. good health determine 1. medical history 2. physical assessment 3. clinical judgment investigator 4. negative urine pregnancy test woman childbearing age . Individuals eligible enrol study : 1. unwilling unable give write informed assent consent participate study . 2. perceive unreliable unavailable duration study period . 3. planning leave area study site end study period . 4. previous suspect disease cause N. meningitidis . 5. household contact and/or intimate exposure individual cultureproven N. meningitidis infection within 60 day prior enrollment . 6. previously immunize meningococcal vaccine . 7. receive investigational nonregistered product ( drug vaccine ) within 28 day prior enrollment expect receive investigational drug vaccine prior completion study . 8. receive licensed vaccine within 14 day ( inactivated vaccine ) 28 day ( live vaccine ) prior enrollment study plan receive vaccine within 30 day study vaccine . ( Exception : Influenza vaccine administer 15 day prior study vaccination least 15 day study vaccination ) 9. experience within 7 day prior enrollment significant acute chronic infection ( example require systemic antibiotic treatment antiviral therapy ) experience fever ( define body temperature ≥38°C ) within 3 day prior enrollment . 10. serious acute , chronic progressive disease ( e.g. , history neoplasm , cancer , diabetes , cardiac disease , autoimmune disease , HIV infection AIDS , blood dyscrasia , sign cardiac renal failure severe malnutrition ) . 11. epilepsy progressive neurological disease . 12. history anaphylaxis , serious vaccine reaction , allergy vaccine component , include latex allergy . 13. know suspected impairment/alteration immune function , either congenital acquire result ( example ) : 1. receive immunosuppressive therapy within 28 day prior enrollment ( systemic corticosteroid administer 5 day , daily dose &gt; 1 mg/kg/day prednisone equivalent 28 day prior enrollment , cancer chemotherapy ) 2. receive immunostimulants 3. receive parenteral immunoglobulin preparation , blood product , and/or plasma derivative within 90 day prior enrollment full length study 14. know bleeding diathesis , condition may associate prolonged bleeding time . 15. condition , opinion investigator , might interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Meningococcal</keyword>
	<keyword>ACWY-CRM</keyword>
	<keyword>Conjugate Vaccine</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Persistence</keyword>
	<keyword>Adults</keyword>
</DOC>